Automotive Anti-Pinch Power Window System Market to Reach $3,611.2 Million by 2023     |    Orthodontic Supplies Market to Reach $5.9 Billion by 2023     |    Automotive HMI Market to Reach $39,695 Million by 2023
P&S Market Research - A market research firm

Biopharmaceuticals Market

P&S Market Research-Biopharmaceuticals Market report

Global Biopharmaceuticals Market Size, Share, Development, Growth and Demand Forecast to 2020 – Industry Insights by Type (Monoclonal Antibodies, Recombinant Proteins, Interferon, Colony-Stimulating Factor, Erythropoietin, Recombinant Human Insulin, Vaccines, Growth Hormones, Purified Proteins and others) and by Application (Oncology, Inflammatory and Infectious Diseases, Metabolic Disorders, Neurological Disorders, Cardiovascular Diseases and Others)

Published: October 2015
Report Code: LS10432
Available Format: pdf
Pages: 115

The global biopharmaceuticals market accounted for $ 160,440.4 million in 2014, and it is expected to grow with a CAGR of 9.6% during 2015-2020. The monoclonal antibodies market segment dominated the global biopharmaceuticals market in 2014 with about 25.8% share; whereas, among application segment, the oncology segment accounted for the highest share of 27% in the global biopharmaceuticals market in the same year. The global biopharmaceuticals market is growing with a high growth rate, due to increasing geriatric population, increasing R&D investments, increasing prevalence of chronic diseases, and technological advancements in biopharmaceuticals which has helped in curing diseases with no available treatment.

 

Biopharmaceuticals Market

Biopharmaceuticals are in huge demand due to the increasing prevalence of chronic diseases, which is one of the key drivers, fuelling the growth of the global biopharmaceuticals market. Chronic diseases are increasing due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity. The increase in chronic diseases worldwide is leading to the growth in the number of hospitalization cases, which is fuelling the demand for biopharmaceuticals. The monoclonal antibodies market grew with an average annual growth rate of over 9.3% during 2011-2014. The oncology market on the other hand, grew with a CAGR of 10.9% during 2011-2014.

The R&D investments in formulation and development of a drug have increased, due to the growing demand for prevention, treatment, and complete curative options for various diseases. Many pharmaceutical companies are focusing on developing more effective products to treat life-threatening diseases and encourage patients to live healthier lives with reduced disabilities. The increasing healthcare investments around the world, is propelling the increase in R&D investments, which is fuelling the growth of the global biopharmaceuticals market.

The increasing aging population is propelling the growth of the global biopharmaceuticals market, as the pool of elder population is more prone to illness due to low immunity levels, and high recovery time consumption. The elderly people are also susceptible to dermatological disorders, such as dermatitis and cellulitis. Moreover, common eye diseases, including glaucoma and age-related macular degeneration (AMD) are also age-related diseases. These age-related disorders would require more effective biopharmaceuticals for their treatment, thus fuelling the demand of the global biopharmaceuticals market.

The technological advancements in biopharmaceuticals, such as target specific approach with high efficiency, are proving to be advantageous in treating various disorders and chronic diseases. Additionally, biopharmaceuticals have the potential to prevent, treat, and heal the diseases completely, which are otherwise difficult to cure or have no available treatment.

The restraints associated with the global biopharmaceuticals market include high cost of biopharmaceuticals and side effects, such as breathing problems, sore throat, allergic reactions, itching, and rashes due to the consumption of biopharmaceuticals. The low-cost biosimilars are posing a threat to the global biopharmaceuticals market. Biosimilar refers to a biological product that is approved by drug related authorities, such as the Food Drug Association (FDA) and is similar in function, safety, and effectiveness; just like the original product manufactured by a different company. Furthermore, the easy availability of low-priced biosimilars of existing biopharmaceuticals is hampering the growth of the global biopharmaceuticals market.

The key companies operating in the global biopharmaceuticals market include AbbVie  Inc, Eli Lilly and Company, Sanofi, Pfizer Inc., Abbott Laboratories, AstraZeneca PLC, Novartis AG, Biogen Idec , Bristol-Myers Squibb Company,  and Amgen Inc.

 

Report Coverage

  • Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
  • Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
  • Uncovers potential demands in the market
  • Porter analysis identifies competitive forces within the market
  • Provides information on the historical and current market size and the future potential of the market
  • Provides sizes of key regional markets using yardsticks of processes, segments, products, end user and technology, etc (as applicable)
  • Highlights the competitive scenario of the market, major competitors, market share, benchmarking, investments and merger acquisitions
  • Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

5100
Group License

Group License authorizes access of the publication upto 5 users.

6100
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

9100
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment